Attribute	Ipamorelin	GHRP-2
Class	GHRP pentapeptide	GHRP hexapeptide
Receptor target	GHS-R1a (ghrelin receptor)	GHS-R1a (ghrelin receptor)
GH pulse potency	Moderate; highly selective for GH	Strong; among the most potent GHRPs
Cortisol elevation	Minimal to none (key distinction)	Meaningful; dose-dependent
Prolactin elevation	Minimal to none	Meaningful; dose-dependent
Appetite stimulation	Minimal	Moderate; less than GHRP-6
Half-life	~2 hours (reported)	~30 minutes (reported)
Common reported doses	100–300 mcg per injection	100–300 mcg per injection

Key Differences

Both Ipamorelin and GHRP-2 act at the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor — stimulating pulsatile GH release from the anterior pituitary. Their shared receptor target and injection-based administration make them superficially similar, but the pharmacological profiles diverge significantly in one critical dimension: hormonal selectivity.

Ipamorelin is among the most selective GHRPs ever developed. It produces a robust GH pulse with minimal stimulation of cortisol, ACTH, or prolactin — a profile that is unusual in the GHRP class, where off-target hormonal activation is common. GHRP-2 produces a notably stronger GH pulse but also meaningfully elevates cortisol and prolactin. For researchers seeking to maximise GH-related effects while minimising HPA axis activation, this distinction is the primary consideration.

The practical implication is straightforward: Ipamorelin is preferred when hormonal selectivity matters — in research contexts where cortisol elevation would counteract the desired anabolic or recovery outcomes. GHRP-2 is selected when raw GH pulse amplitude is the priority and the cortisol and prolactin elevation are considered acceptable trade-offs.

Detailed Comparison

Hormonal Selectivity — the Defining Distinction

Ipamorelin was developed specifically to address the selectivity limitations of earlier GHRPs. In clinical studies, Ipamorelin at doses of 200 mcg produced robust GH release comparable to GHRP-2 at equivalent doses, while producing no significant change in cortisol, ACTH, or prolactin levels. This selectivity profile is attributable to Ipamorelin's specific binding conformation at GHS-R1a, which preferentially activates the Gαs/cAMP pathway for GH secretion over the pathways that activate adrenocortical and lactotroph responses.

GHRP-2, by contrast, activates GHS-R1a more broadly, producing GH release alongside meaningful cortisol and prolactin elevation. Research has documented GHRP-2-induced cortisol elevation in both human and animal studies; this cortisol response is transient and dose-dependent but is a consistent and clinically recognised feature of GHRP-2 pharmacology. For researchers who view cortisol elevation as counterproductive to recovery, anabolic, or performance-oriented research goals, this is a meaningful distinction.

GH Pulse Amplitude

GHRP-2 is generally reported to produce a somewhat larger peak GH pulse than Ipamorelin at equivalent doses in direct comparison studies. For researchers whose primary objective is maximal GH stimulation — for IGF-1 elevation, body composition, or GH-axis diagnostic purposes — this potency advantage is the primary rationale for selecting GHRP-2 over Ipamorelin.

In combination with a GHRH analogue (CJC-1295 or Sermorelin), the synergistic amplification of GH release tends to diminish the practical significance of this pulse amplitude difference — both GHRPs produce large synergistic pulses in combination with GHRH analogues, and the selectivity advantage of Ipamorelin becomes more relevant.

Appetite and Ancillary Effects

Ipamorelin produces minimal appetite stimulation — consistent with its selective GHS-R1a pharmacology. GHRP-2 produces moderate appetite stimulation via hypothalamic ghrelin receptor activation, though less pronounced than GHRP-6. For researchers where appetite management is a consideration, Ipamorelin's lower appetite stimulation is an additional distinction.

Reported Side Effects

Ipamorelin — Reported side effects in research and anecdotal accounts include mild injection site reactions, transient flushing, and occasional headache. The minimal cortisol and prolactin effects mean that hormonal side effects associated with other GHRPs are rarely reported.

GHRP-2 — Reported side effects in research and anecdotal accounts include cortisol elevation (transient, dose-dependent), prolactin elevation (transient, dose-dependent), moderate appetite stimulation, water retention consistent with GH elevation, and injection site reactions. Some anecdotal researchers describe managing the cortisol response by administering in the morning when the cortisol awakening response is naturally highest.

Can They Be Combined?

Combining Ipamorelin and GHRP-2 is uncommon in anecdotal research accounts, as both compounds act at the same GHS-R1a receptor. Combining two GHS-R1a agonists would be largely redundant — the receptor is already maximally or near-maximally stimulated by either compound alone at recommended doses. The practical co-administration approach is to pair either GHRP with a GHRH analogue (CJC-1295 or Sermorelin) for synergistic GH release.

See the Ipamorelin vs CJC-1295 and Ipamorelin vs Sermorelin comparisons for GHRP + GHRH combination context.

Which to Consider

Researchers commonly choose Ipamorelin when hormonal selectivity is a priority — specifically when minimising cortisol and prolactin elevation is important for the research context. Ipamorelin is the most commonly reported GHRP among researchers seeking a clean GH pulse without off-target hormonal effects.

Researchers commonly choose GHRP-2 when raw GH pulse amplitude is the primary objective, when the compound is being used diagnostically for GH reserve assessment (a documented clinical application), or when the cortisol and prolactin elevation are considered acceptable in the specific research context.

Frequently Asked Questions

Does GHRP-2 raise cortisol significantly?

Yes — cortisol elevation following GHRP-2 administration is documented in published clinical studies and is a consistent pharmacological feature of the compound. The elevation is dose-dependent and transient, typically peaking within 30 minutes of administration and returning to baseline within 1–2 hours. Research accounts describe monitoring cortisol responses when using GHRP-2 at higher doses over extended periods.

Is Ipamorelin always the better choice?

Not universally. Ipamorelin's selectivity advantage is most relevant when cortisol minimisation is a research priority. For applications where maximum GH pulse amplitude is the goal — such as GH axis stimulation for body composition, or GH reserve diagnostic testing — GHRP-2's potency advantage may be the more relevant consideration. "Better" depends entirely on the research objective and acceptable trade-off profile.

Which pairs better with CJC-1295?

Both pair with CJC-1295 (or Sermorelin) for synergistic GH release. Ipamorelin is more commonly reported in the combination context — particularly the Ipamorelin / CJC-1295 pairing, which is among the most widely documented GH research stacks. The selectivity advantage of Ipamorelin makes it a natural choice when the combination stack is intended for extended use where cortisol exposure is a concern.